CIPLA | Bearish Reversal Setup — Channel Break Targets The LiquiCipla LtdNSE_DLY:CIPLABigBeluga By analyzing the 🇮🇳 #CIPLA (Cipla) chart on the 4H timeframe, we can see that the stock is showing early signs of a bearish reversal after a corrective rally into a key supply area. The structure is coiling, and a break of the rising channel would confirm the next move lower. 📊 4H Timeframe On the 4H, the story starts with an external CHoCH that broke the prior bullish structure and shifted the higher-timeframe character to bearish. From the lows, price then began a corrective rally back up — and along the way it built internal bullish structure (an i CHoCH, followed by i BOS and another i BOS) as it climbed inside a rising channel. That corrective rally carried price straight into the Flip Zone (₹1,475.70 – ₹1,539.45) — the former support that now acts as resistance — where it executed a Liquidity Sweep, running the stops above before stalling. This is the classic setup for a reversal: a corrective rally into a flip zone, a liquidity grab, and now price rolling over. Price is currently trading around ₹1,419.50. The key structural level to watch is the Internal Protected Low at ₹1,342.75 — as long as it holds, the internal bullish channel is still technically alive, but a decisive break below it (together with a break of the rising channel) confirms the bearish leg and opens the path down toward the sell-side liquidity (SSL) resting at ₹1,167.05. 🎯 The Bias My base case leans bearish, but it's conditional on confirmation. Price has rejected from the Flip Zone after a liquidity sweep — a clean bearish signal — but the internal structure won't be broken until price closes below the Internal Protected Low (₹1,342.75) and breaks the rising channel. On that trigger, the draw is toward the SSL at ₹1,167.05. In my view, as long as price stays capped below the Flip Zone (₹1,475.70 – ₹1,539.45), the rejection favours the sellers — but if buyers reclaim that zone with a decisive close, the bearish idea is invalidated and the corrective rally could extend higher within the channel. 📰 Fundamental Backdrop The technical setup arrives right before a major catalyst. Cipla's board meets on July 23, 2026 to approve its Q1 FY27 results, with an earnings call the same day — flagged across the sector as a key volatility trigger for pharma. The fundamental backdrop is genuinely constructive: Cipla just posted its highest-ever annual revenue of ₹28,000 crore for FY26, with the India business crossing ₹12,500 crore (up 9% YoY) and North America delivering $780 million, and its regulatory picture is improving after the Pithampur Unit 1 received a favorable VAI status from the USFDA — de-risking future US filings. Analysts are broadly positive (consensus "Buy," average target around ₹1,457), and the company is pushing its 'One-India' strategy and complex US generics as growth levers. But there are real risks to respect: US generic pricing pressure persists, margins are expected to hold in a 23–25% range rather than expand, and pharma stocks have historically shown sharp post-earnings swings — Cipla itself has dropped 6%+ on disappointing prints before. Net-net: the fundamentals are solid, but the July 23 result is a binary event that could easily trigger the exact channel break the chart is setting up — making risk management essential into the print. This analysis will be updated as the market evolves. If this breakdown added value, drop a like 👍 and a comment 💬 to support the work — and share where you see Cipla heading next! Best Regards, BigBeluga 🐳